There are> 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of
action currently approved by the US Food and Drug Administration for the treatment of …

Multiple sclerosis (MS) is characterized by autoimmune inflammation and subsequent
neurodegeneration. It is believed that early in the disease course, proinflammatory T cells …

Objective To assess whether it is feasible to establish specific cut-off values able to
discriminate 'physiological'or 'pathological'brain volume rates in patients with multiple …

Background Glatiramer acetate, approved for the treatment of relapsing-remitting multiple
sclerosis, reduces relapses and disease activity and burden monitored by MRI. We …

Brain atrophy has emerged as a clinically relevant component of disease progression in
multiple sclerosis. Progressive loss of brain tissue bulk can be detected in vivo in a sensitive …

Purpose of Review This review presents the hypothesis that loss of neurologic reserve
explains onset of progressive multiple sclerosis (PrMS). Recent Findings Evidence …

Objective: We investigated the determinants and clinical correlations of MRI-detected brain
volume loss (BVL) among patients with relapsing-remitting multiple sclerosis from the phase …

The etiology of neurodegenerative disorders is multifactorial and consists of an interaction
between aging, environmental factors, and genetic predisposition. Neuronal cell loss in …

Leakage of the blood–brain barrier (BBB) is a common pathological feature in multiple
sclerosis (MS). Following a breach of the BBB, albumin, the most abundant protein in …

Background: Brain atrophy, in excess of that seen with normal aging, has been observed
early in the clinical course of relapsing-remitting multiple sclerosis (RRMS). Previous work …